截至2025年12月31日收盘，新华制药（000756）报收于15.41元，较上周的15.81元下跌2.53%。本周， 新华制药12月29日盘中最高价报15.85元。12月31日盘中最低价报15.4元。新华制药当前最新总市值 106.29亿元，在化学制药板块市值排名49/150，在两市A股市值排名1817/5181。 公司同时获得缬沙坦胶囊药品注册证书（国药准字H20256391），注册分类为化学药品4类，用于轻、 中度原发性高血压治疗，属医保甲类品种。2024年中国公立医疗机构该产品销售额约为18.2亿元。两项 获批有助于提升公司产品竞争力，但销售受政策与市场因素影响，存在不确定性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：新华制药获间苯三酚注射液药品注册证书，拓展新市场。 公司公告汇总：缬沙坦胶囊获批，丰富心血管产品线。 公司公告汇总：间苯三酚注射液2024年公立医疗机构销售额约9亿元。 公司公告汇总：缬沙坦胶囊2024年公立医疗机构销售额约18.2亿元。 本周关注点 公司公告汇总 新华制药近日取得间苯三酚 ...

格隆汇12月29日丨新华制药(000756.SZ)公布，收到国家药品监督管理局核准签发的缬沙坦胶囊《药品 注册证书》。本品用于治疗轻、中度原发性高血压。 ...

Group 1 - Nan Mining Group signed a procurement contract for iron ore equipment worth 3 billion yuan with Lanyan Weiye Mineral Processing Co., Ltd., for a project processing over 4.6 million tons of ore annually, with an estimated operational cost of 3 billion yuan over 10 years [1] - Guangdong Yuedian A's Dapu Power Plant Phase II Project's Unit 4 has commenced commercial operation, with a total investment of 8.122 billion yuan and an expected annual power generation of 9 billion kilowatt-hours [2] - China Energy Engineering's subsidiary won an EPC general contracting project in Shaanxi Province with a bid amount of approximately 6.864 billion yuan, covering ecological governance, infrastructure, urban renewal, and water conservancy projects, with a total construction period of 36 months [3] Group 2 - ST Dongtong's stock will resume trading on December 30, 2025, entering a delisting arrangement period of 15 trading days, with the last trading date expected to be January 21, 2026 [4] - Roman Co.'s subsidiary signed a contract for a computing power service project worth approximately 156 million yuan with Tianjin Maoyuan Equipment Leasing Co., Ltd. and China Merchants Intelligent Supply Chain Service Co., Ltd. [5] - Hangzhou Thermal Power plans to sign a three-year coal purchase contract with Shanghai Yitai Shenpu for a total of 9 million tons, ensuring stable coal supply from 2026 to 2028 [6] Group 3 - Caitong Securities received approval from the China Securities Regulatory Commission to publicly issue bonds totaling no more than 15 billion yuan [7] - Qipai Technology's application for a stock issuance to specific investors has been approved by the Shanghai Stock Exchange [8] - China Software plans to sell 555 units of X86 servers and two properties to optimize idle assets, with a total estimated value of approximately 6.758 million yuan [10] Group 4 - Xinhua Medical received medical device registration certificates for two products, including an interleukin-6 test kit and a dual test kit for procalcitonin/interleukin-6 [11] - Shandong Haohua announced the resignation of Deputy General Manager Yuan Falin due to personal reasons [12] - Haixiang Pharmaceutical's invested company NWRD06 injection has completed the enrollment of the first subject in its Phase II clinical trial [13] Group 5 - Tiantong Co. terminated the absorption merger of its wholly-owned subsidiary Tiantong Rijing Precision Technology Co., Ltd., retaining its independent legal status [14] - Ruima Precision's subsidiary received a project designation for automotive air suspension systems, with an estimated sales revenue of approximately 1.342 billion yuan over a six-year lifecycle [15] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Qianxing Future to enhance collaboration in the development and manufacturing of quadruped robots [16] Group 6 - Huali Co. terminated the acquisition of a 51% stake in Zhongke Huilian due to failure to reach consensus on key transaction terms [17] - Acolyte's olefin copolymer has passed customer verification and is now in bulk supply for the optical lens sector [18] - Tianjian Technology signed a supplementary agreement for military product price adjustments, expecting a revenue reduction of approximately 256 million yuan [19] Group 7 - Southeast Network Framework won an EPC project bid for the "China Vision Valley Industrial Base" with a total bid amount of 888 million yuan [20] - Baodi Mining plans to acquire 87% of Congling Energy for a total of 685 million yuan through a combination of cash and share issuance [21] - Heng Rui Pharmaceutical received clinical trial approval for multiple drugs, including HRS-6257 tablets for treating acute and chronic pain [22] Group 8 - Zhongxin Saike received a dividend of 60 million yuan from its wholly-owned subsidiary [23] - ST Songfa's subsidiary signed a contract for the construction of an oil tanker with a total contract value of approximately 80 to 100 million USD [24] - China Resources Double Crane received clinical trial approval for hydroxocobalamin injection, aimed at treating metabolic disorders in children [25][26]

每经头条（nbdtoutiao）——直击茅台经销商大会：2000多人周末齐聚！重大变革公布：涉及茅台酒价 格、分销等，董事长陈华：经销商不能再"躺着赚钱" （记者 王晓波） 每经AI快讯，新华制药（SZ 000756，收盘价：15.63元）12月29日晚间发布公告称，近日，山东新华制 药股份有限公司收到国家药品监督管理局核准签发的缬沙坦胶囊《药品注册证书》。 截至发稿，新华制药市值为108亿元。 ...

新华制药12月29日公告，公司近日收到国家药品监督管理局核准签发的缬沙坦胶囊《药品注册证书》。 该药品为处方药，化学药品4类，规格为80mg，用于治疗轻、中度原发性高血压。公司申报的缬沙坦胶 囊于2025年12月获得药品注册证书，有利于丰富公司治疗心血管疾病产品系列，提升公司综合竞争力。 因药品销售业务易受到国内医药行业政策变动、招标采购、市场环境变化等因素影响，存在不确定性。 ...

人民财讯12月29日电，新华制药（000756）12月29日公告，公司近日收到国家药监局核准签发的缬沙坦 胶囊、间苯三酚注射液《药品注册证书》。缬沙坦胶囊用于治疗轻、中度原发性高血压。间苯三酚注射 液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉 挛性疼痛。 ...

新华制药公告称，近日收到国家药监局核准签发的缬沙坦胶囊《药品注册证书》。该药品规格为 80mg，属处方药、化学药品4类，用于治疗轻、中度原发性高血压，为医保甲类品种。2024年9月公司 递交上市许可申报资料并获受理，2025年12月获批。2024年中国公立医疗机构缬沙坦胶囊销售额约18.2 亿元。获批有利于丰富公司心血管疾病产品线，提升竞争力，但药品销售受政策、市场等因素影响，存 在不确定性。 ...

新华制药申报的缬沙坦胶囊于2025年12月获得药品注册证书，有利于丰富公司治疗心血管疾病产品系 列，提升公司综合竞争力。 山东新华制药（000756）股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新华制 药"或"本公司")收到国家药品监督管理局核准签发的缬沙坦胶囊(以下简称"本品")《药品注册证书》。 ...

格隆汇12月29日丨山东新华制药股份(00719.HK)发布公告，近日，公司收到国家药品监督管理局核准签 发的缬沙坦胶囊《药品注册证书》。本品用于治疗轻、中度原发性高血压。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新 华制药"或"本公司")收到国家药品监督管理局核准签发的缬沙坦胶囊(以下简称"本品")《药品注册证 书》。 新华制药申报的缬沙坦胶囊于2025年12月获得药品注册证书，有利于丰富公司治疗心血管疾病产品系 列，提升公司综合竞争力。 ...